This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Various				
Myeloproliferative disorder; leukemia	Rho-associated coiled-coil containing protein kinase 1 (ROCK1)	<i>In vitro</i> and mouse studies suggest ROCK inhibition could help treat hematological malignancies driven by mutant oncogenes. In human cells expressing a subset of mutant tyrosine kinases and in cells from patients with acute myeloid leukemia (AML), ROCK inhibition suppressed growth compared with no treatment. In xenograft mouse models of myeloproliferative disorder and leukemia, ROCK inhibitors including Eril fasudil prolonged survival compared with saline control. Next steps include testing Eril in patients with cancer. Asahi Kasei Pharma Corp. markets Eril to treat aneurysm.	Patent application filed in the U.S. for the use of fasudil to treat mastocytosis and AML; available for licensing	Mali, R. <i>et al. Cancer Cell</i> ; published online Sept. 12, 2011; doi:10.1016/j.ccr.2011.07.016 Contact: Reuben Kapur, Indiana University School of Medicine, Indianapolis, Ind. e-mail: rkapur@iupui.edu
SciBX 4(38); doi:10.1038/scibx.2011.1074 Published online Sept. 29, 2011				